Recruiting Clinical Trials

Displaying 41 - 50 of 238 result(s)
Study Title Condition Phase Location
KontRASt-03: A Phase Ib/II, Multicenter, Open-label Platform Study of JDQ443 With Select Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Colorectal Cancer, Colorectal Carcinoma, Colorectal Neoplasms, Colorectal Tumors, Neoplasms, Colorectal Phase 1, Phase 2
  • Country: 
    Belgium
  • Country: 
    Korea, Republic of
A 52 Week, Multi-center, Randomized, Double-blind Placebo-controlled Study to Assess the Clinical Efficacy and Safety of Ligelizumab (QGE031) in Decreasing the Sensitivity to Peanuts in Patients With Peanut Allergy Allergy, Peanut Phase 3
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    Canada
  • Country: 
A Participant- and Investigator-blinded, Randomized, Placebo-controlled, Multicenter, Platform Study to Investigate Efficacy, Safety, and Tolerability of Various Single Treatments in Participants With Idiopathic Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis Phase 2
  • Country: 
    Australia
Exploratory PLatform Trial on Anti-Inflammatory Agents in Alzheimer's Disease (EXPLAIN-AD): A Randomized, Placebo-controlled, Multicenter Platform Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Various Anti-inflammatory ... Mild Cognitive Impairment, Alzheimer Disease Phase 2
  • Country: 
    United States
  • Country: 
    Finland
  • Country: 
    Iceland
  • Country: 
VICTORION REAL: An International Prospective Real-world Study to Evaluate the Effectiveness and Adherence of Inclisiran Plus Standard of Care Lipid-lowering Therapy Compared to Standard of Care Therapy Alone in Patients With Primary Hypercholesterole ... Primary Hypercholesterolemia, Mixed Dyslipidemia Not Given
  • Country: 
    Switzerland
Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program Not Applicable
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    Austria
  • Country: 
Open Label, Multi-center, Phase IV Study of Ruxolitinib or Ruxolitinib and Panobinostat Combination, for Patients Who Have Completed Prior Global Novartis or Incyte Sponsored Studies Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia, Thalassemia Phase 4
  • Country: 
    Belgium
  • Country: 
    China
  • Country: 
    India
  • Country: 
A Two-part, Randomized, Investigator- and Participant- Blinded, Placebo-controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MHS552 in Adult Participants With Systemic Lupus Erythemato ... Lupus Erythematosus, Systemic Phase 1
  • Country: 
    Germany
An Open-label, Phase I, Dose Escalation, Expansion Study of MGY825 in Adult Patients With Advanced Non-small Cell Lung Cancer Non-small Cell Lung Cancer Phase 1
  • Country: 
    United States
  • Country: 
    Germany
  • Country: 
    Japan
  • Country: 
A Phase II, Randomized (1:1) Open Label Study to Assess the Efficacy and Safety of Eltrombopag in Combination With Dexamethasone Compared to Dexamethasone, as First-line Treatment in Adult Patients With Newly Diagnosed Immune Thrombocytopenia Immune Thrombocytopenia (ITP) Phase 2
  • Country: 
    Germany